China’s Biotech Titans Are Rewriting the Global Pharma Playbook
Quick Reads
- Chinese biotech stocks on the Hong Kong Stock Exchange surged over 100% in 2025, driven by record licensing deals.
- China accounted for 32% of global biotech licensing deal value in Q1 2025, up sharply from 21% in 2024.
- AstraZeneca invested $2.5 billion in Beijing in 2025, signalling deep Western confidence in China’s pharma ecosystem.
- BeiGene, now BeOne Medicines, generated $3.8 billion in global revenue last year on the back of two blockbuster cancer drugs.
- Despite BIOSECURE Act threats, WuXi AppTec hit a record RMB59.9 billion backlog through Q3 2025.
China’s biotech titans are no longer playing catch-up. They are now setting the pace for global pharmaceutical innovation. For decades, Western companies dominated drug discovery and development. Today, that story is rapidly changing.
As of mid-2025, Chinese biotech stocks on Hong Kong Exchange jumped over 100%, driven by licensing and business development growth. Furthermore, 14 Chinese biopharma and medical device companies listed in Hong Kong, raising HK$18.2 billion, about four times 2024 totals.
The rise is not accidental. Over the last decade, mainland China has transformed into a global biopharma leader, driven by ambitious policies, R&D investment, and a reformed regulatory landscape. Key national strategies like “Made in China 2025” and “Healthy China 2030” have built a powerful innovation ecosystem.
Leading this charge are China’s biotech titans, WuXi AppTec, BeiGene, and Jiangsu Hengrui Pharmaceuticals. WuXi AppTec, for instance, operates as a one-stop shop for pharmaceutical R&D, covering everything from early-stage drug discovery to manufacturing. Meanwhile, Jiangsu Hengrui holds 30 commercialized drugs in China and 20 more across the EU, US, and Japan, with 100 investigational drugs in over 400 ongoing clinical trials.
BeiGene, now rebranded as BeOne Medicines, has also made notable strides. The oncology-focused firm secured approximately $3.8 billion in global revenue last year, driven by its blockbuster blood cancer drug Brukinsa and esophageal cancer treatment Tevimbra.
Global deal-making reflects this momentum strongly. In Q1 2025 alone, Chinese companies accounted for 32% of global biotech licensing deal value, up from 21% in both 2023 and 2024. Additionally, 35% of all deals in 2025 have originated from China.
Western pharmaceutical giants are also responding to China’s biotech titans with enormous investments. In March 2025, AstraZeneca announced a $2.5 billion investment in Beijing to establish its sixth global strategic R&D centre. Moreover, AstraZeneca paid $5 billion to CSPC Pharmaceutical Group for access to its AI platform and a portfolio of preclinical cancer drugs.
AI is also rapidly reshaping the industry. China has formally listed AI-driven drug discovery as a priority in its Five-Year Plan for 2025, with many Chinese firms now attracting significant interest from Western pharmaceutical companies.
Nevertheless, challenges remain for China’s biotech titans. The proposed US BIOSECURE Act would prohibit drugmakers holding federal contracts from using Chinese firms like WuXi AppTec and WuXi Biologics after 2032. Geopolitical tensions continue to create headwinds. Yet despite these pressures, WuXi AppTec delivered strong double-digit revenue and profit growth in the first three quarters of 2025, with its backlog reaching a record RMB59.9 billion.
China’s biotech titans have clearly moved from imitators to innovators. As global demand for affordable, cutting-edge medicines grows, their influence will only deepen.
